scholarly journals Safety and Immunogenicity of Mix-Match of Vaccines -Covishield and Covaxin – a Pilot Study

2022 ◽  
Author(s):  
Bhanu Prakash Reddy Attunuru ◽  
Podduturi Naveenchander Reddy ◽  
Sasikala Mitnala ◽  
Gujjarlapudi Deepika ◽  
Sadhana Yelamanchili Veturi ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Observational Study ◽  
Immune Responses ◽  
Prospective Observational Study ◽  
Single Center ◽  
Rt Pcr ◽  
Combination Vaccines ◽  
Mix And Match ◽  
Immunogenic Response

Abstract This single-center prospective observational study was conducted to assess the safety and immunogenicity of combination vaccines AstraZeneca’s ChAdOx1-nCov-19 (Covishield in India) and inactivated whole virion BBV152 (Covaxin). A total of 330 unvaccinated healthy volunteers were screened for SARS-COV2 seropositivity. RT PCR tests were conducted for seronegative volunteers (n =44). They were randomly assigned to four groups and given either same or mixed vaccines at an interval of 4 weeks between the two doses. Mix and match of vaccines did not evoke any adverse events. Combination of vaccines elicited similar immune responses in 4 groups. They were further studied dividing into homologous and heterologous vaccine groups. In Conclusion, Combination vaccines are safe and immunogenic and heterologous vaccines elicit better immunogenic response.

scholarly journals Safety and Immunogenicity of Combination of Vaccines – Covishield and Covaxin – a Pilot Study

2021 ◽  
Author(s):  
Bhanu Prakash Reddy Attunuru ◽  
Podduturi Naveenchander Reddy ◽  
Sasikala Mitnala ◽  
Gujjarlapudi Deepika ◽  
Sadhana Yelamanchili Veturi ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Observational Study ◽  
Immune Responses ◽  
Healthy Volunteers ◽  
Prospective Observational Study ◽  
Single Center ◽  
Rt Pcr ◽  
Combination Vaccines ◽  
Mix And Match

Abstract This single-center prospective observational study was conducted to assess the safety and immunogenicity of combination vaccines AstraZeneca’s ChAdOx1-nCov-19 (Covishield in India) and inactivated whole virion BBV152 (Covaxin). A total of 330 unvaccinated healthy volunteers were screened for SARS-COV2 seropositivity. RT PCR tests were conducted for seronegative volunteers (n =44). They were randomly assigned to four groups and given either same or mixed vaccines at an interval of 4 weeks between the two doses. Mix and match of vaccines did not evoke any adverse events. Combination of vaccines elicited similar immune responses in 4 groups. In Conclusion, Combination vaccines are safe and immunogenic.

scholarly journals Premedication practices for tracheal intubation in neonates transported by French medical transport teams: a prospective observational study

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e034052 ◽  
Author(s):  
Ricardo Carbajal ◽  
Noella Lode ◽  
Azzedine Ayachi ◽  
Ourida Chouakri ◽  
Véronique Henry-Larzul ◽  
...  
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Drug Regimen ◽  
Muscle Rigidity ◽  
Neonatal Transport ◽  
Registration Number ◽  
Medical Transport ◽  
The Mean ◽  
Paris Region

ObjectivesPremedication practices for neonatal tracheal intubations have not yet been described for neonatal transport teams. Our objective is to describe the use of sedation/analgesia (SA) for tracheal intubations and to assess its tolerance in neonates transported by medical transport teams in France.SettingThis prospective observational study was part of the EPIPPAIN 2 project and collected around-the-clock data on SA practices in neonates intubated by all five paediatric medical transport teams of the Paris region during a 2-month period. Intubations were classified as emergent, semiemergent and non-emergent. Sedation level and conditions of intubation were assessed with the Tonus, Reactivity, Awareness and Conditions of intubation to Help in Endotracheal intubation Assessment (TRACHEA score). The scores range from 0 to 10 representing an increasing ladder from adequate to inadequate sedation, and from excellent to very poor conditions of intubation.Participants40 neonates intubated in 28 different centres.ResultsThe mean (SD) age was 34.9 (3.9) weeks, and 62.5% were intubated in the delivery room. 30/40 (75%) of intubations were performed with the use of SA. In 18/30 (60.0%) intubations performed with SA, the drug regimen was the association of sufentanil and midazolam. Atropine was given in 19/40 intubations. From the 16, 21 and 3 intubations classified as emergent, semiemergent and non-emergent, respectively, 8 (50%), 19 (90.5%) and 3 (100%) were performed with SA premedication. 79.3% of intubations performed with SA had TRACHEA scores of 3 or less. 22/40 (55%) infants had at least one of the following adverse events: muscle rigidity, bradycardia below 100/min, desaturation below 80% and nose or pharynx–larynx bleeding. 7/24 (29.2%) of those who had only one attempt presented at least one of these adverse events compared with 15/16 (93.8%) of those who needed two or more attempts (p<0.001).ConclusionSA premedication is largely feasible for tracheal intubations performed in neonates transported by medical transport teams including intubations judged as emergent or semiemergent.Trial registration numberNCT01346813; Results.

Long‐term efficacy of add‐on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: A single center prospective observational study

Epilepsia ◽  
2019 ◽  
Vol 60 (11) ◽  
pp. 2255-2262 ◽  
Author(s):  
Anna Rosati ◽  
Alessandra Boncristiano ◽  
Viola Doccini ◽  
Alessandra Pugi ◽  
Tiziana Pisano ◽  
...  
Keyword(s):  
Young Adults ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Adolescents And Young Adults ◽  
Single Center ◽  
Term Efficacy

scholarly journals Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Klemens Budde ◽  
Thomas Rath ◽  
Volker Kliem
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Kidney Transplant ◽  
Prospective Observational Study ◽  
Erythropoietin Receptor ◽  
Study Entry ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Receptor Activator ◽  
Continuous Erythropoietin Receptor Activator

In a multicenter, prospective, observational study of 279 kidney transplant recipients with anemia, the efficacy and safety of once-monthly continuous erythropoietin receptor activator (C.E.R.A.) were assessed to a maximum of 15 months. The main efficacy variable was the proportion of patients achieving a hemoglobin level of 11-12 g/dL at each of visits between months 7 and 9. At study entry, 224 patients (80.3%) were receiving erythropoiesis stimulating agent (ESA) therapy including darbepoetin alfa (98), epoetin beta (61), and C.E.R.A. (45). The mean (SD) time between C.E.R.A. applications was 34.0 (11.9) days. Among 193 patients for whom efficacy data were available, mean (SD) hemoglobin was 11.1 (0.99) g/dL at study entry, 11.5 (1.1) g/dL at month 7, 11.6 (1.3) g/dL at month 9, and 11.4 (1.1) g/dL at month 15. During months 7–9, 20.7% of patients had all hemoglobin values within the range 11-12 g/dL and 64.8% were within 10–13 g/dL. Seven patients (2.5%) discontinued C.E.R.A. due to adverse events or serious adverse events. In this observational trial under real-life conditions, once-monthly C.E.R.A. therapy achieved stable hemoglobin levels in stable kidney transplant recipients with good tolerability, and with no requirement for any dose change in 43% of patients.

Sign in / Sign up

Export Citation Format

Share Document